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Background. Cognitive complaints are gaining more attention as they may represent 
an early marker of increased risk for AD in individuals without objective decline at standard 
neuropsychological examination.  
Objective. Our aim was to assess whether cognitive complaints in late middle-aged 
individuals not seeking medical help are related to objective cognitive outcomes known as 
early markers for AD risk, concomitant affective state, and amyloid-β (Aβ) burden. 
Methods. Eighty-seven community-based cognitively normal individuals aged 50-69 
years underwent neuropsychological assessment for global cognition, using Preclinical 
Alzheimer’s Cognitive Composite 5 (PACC5) score, and a more specific episodic memory 
measure. Affective state was based on self-assessment questionnaires for depression and 
anxiety. Aβ PET burden was assessed via [18F]Flutemetamol (N=84) and [18F]Florbetapir 
(N=3) uptake. Cognitive complaints were evaluated using Cognitive Difficulties Scale. 
Results. Higher cognitive complaints were significantly associated with lower episodic 
memory performance and worse affective state. Moreover, higher level of cognitive complaints 
was related to higher (but still sub-clinical) global Aβ accumulation (at uncorrected 
significance level). Importantly, all three aspects remained significant when taken together in 
the same statistical model, indicating that they explained distinct parts of variance.  
Conclusion. In healthy Aβ negative late middle-aged individuals, a higher degree of 
cognitive complaints is associated with lower episodic memory efficiency, more anxiety and 
depression, as well as, potentially, with higher Aβ burden, suggesting that complaints might 
signal subtle decline. Future studies should untangle how cognitive complaints in healthy aging 










Preclinical Alzheimer’s disease (AD) is characterized by normal cognition on standard 
neuropsychological tests and the presence of AD-related biomarkers referring to pathological 
protein accumulation in the brain, i.e., amyloid-β (Aβ) plaques and tau neurofibrillary tangles, 
irrespective of the status of neurodegeneration [1–3]. However, measurement of AD 
biomarkers using cerebrospinal fluid (CSF) assessment or positron emission tomography 
(PET) is invasive, demanding and costly. In addition, the abnormal value for these biomarkers 
in cognitively normal individuals does not predict AD symptom outbreak but rather represents 
a marker of increased risk for developing AD [4]. Therefore, the identification of other less 
invasive markers, which could help to detect individuals with a higher risk for AD-related 
pathologies in the general population without initial invasive assessment, is of particular 
importance.  
The concept of Subjective Cognitive Decline (SCD) has been developed in that 
framework [5–7]. SCD might be described as a broad spectrum of cognitive complaints 
reported by individuals without objective decline at neuropsychological examination [5]. 
Although not specific, SCD is associated with an increased risk for subsequently developing 
AD, and may also be considered as a preclinical AD stage preceding mild cognitive impairment 
(MCI) [7]. According to its definition, the presence of SCD is not linked to impaired objective 
cognition. Nevertheless, in most cases, cognitive scores match patients’ complaints, such that 
higher level of SCD is related to lower (but still normal) performance on global cognition [8,9], 




A series of self and informant based questionnaires have been developed to quantify 
cognitive difficulties experienced by individuals in the general population or memory clinics 
[7,11–16]. Unfortunately, there is no consensus about which questionnaire and cut-off 
differentiate best SCD individuals from those without SCD. The SCD-Initiative [17] 
recommended the use of two main criteria for SCD diagnosis in clinical settings: (1) self-
experience of persistent decline in cognition compared to previous normal status, a condition 
which is not related to an acute event; (2) normal performance on standardized 
neuropsychological tests, adjusted for sex, age, and education. The latter criterion, i.e., lack of 
objective cognitive decline, is the reason why SCD is not considered as a clinical category in 
the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5). In contrast, medical 
conditions characterized by objective cognitive decline, such as MCI and Alzheimer’s disease  
correspond to mild and  major neurocognitive disorder respectively (mild NCD or major NCD) 
in DSM-5 classification [18]. It is also important to note, that one diagnostic criterion of mild 
NCD includes “concern of the individual, a knowledgeable informant, or the clinician” for 
“evidence of modest cognitive decline from a previous level of performance in one or more 
cognitive domains” [19]. Therefore, in terms of DSM-5, SCD could sometimes, but not always, 
be a precursor to mild NCD. Furthermore, active medical help seeking is considered as an 
additional risk factor of future objective cognitive decline [17,20]. Only a fraction of 
individuals with cognitive concerns seek for medical help, however [21]. 
Age-related brain changes associated with AD, including deposits of Aβ and tau 
proteins, begin as early as in late middle-age (i.e., ~ 50 y) [22–25]. Similarly, several cognitive 
functions such as processing speed, episodic memory and executive functions begin to decline 
already in midlife [26–31]. Previous studies focusing on SCD included patients that were 
usually 70 years or older [32–38], whereas middle-aged cohorts remain underrepresented 




important AD-related genetic risk factor, into account [34,39]. Consequently, participants 
included in these studies may represent a group with a higher AD risk [17]. Furthermore, the 
link between SCD and affective state is not well understood and whether affective issues can 
be observed beyond objective cognitive difficulties is not established [41–43]. Therefore, 
assessing whether cognitive complaints in late midlife are related to AD-related features both 
at the cognitive and brain level is of prime importance to further establish SCD as an early 
marker for AD risk, that could provide a large time window for prevention strategies [44,45]. 
Consequently, the present study aimed to explore whether cognitive complaints in late 
middle-aged individuals (50-69 years) not seeking medical help are related to objective 
cognitive outcomes known as early markers for AD risk, or if other variables associated to 
increased risk for AD (depression and anxiety status, Aβ PET burden) explain the subjective 
feeling of cognitive decline. Objective cognitive measures, affective state and continuous Aβ 
PET values were considered jointly to assess whether they differentially explain cognitive 
complaints, including APOE genotype as a covariate. Given the good health status and 
relatively young age of our target population, we expected that Aβ burden would remain low 
(or sub-clinical). Our hypothesis was that higher level of cognitive complaints would be related 
to lower (but still within normal range) scores for global cognition and episodic memory, worse 
subclinical affective state, and higher global Aβ burden.  
 
MATERIALS AND METHODS 
Experimental design. Participants were enrolled in a multi-modal study designed to 
identify biomarkers and lifestyle factors associated with normal cognitive aging in the context 
of preclinical dementia (the Cognitive Fitness in Aging study, COFITAGE, with trial 




cognition through neuropsychological examination, cognitive complaints and affective state 
via self-report questionnaires, and we also assessed Aβ via PET imaging. All participants also 
underwent quantitative multi-parametric magnetic resonance imaging (MRI) acquisitions for 
subsequent pre-processing of PET data. 
Participants were healthy late middle-aged (50 to 69 y.) community-dwelling French 
speaking men and women (Table 1; N = 87; 60 women [69%]) not actively seeking for help 
in memory clinics. They were recruited in social events for seniors, by advertising in local 
newspapers and by word of mouth. The study was presented as an exploration of the biological 
and psychological mechanisms implicated in sleep, cognition and aging. No participants 
reported any recent history of neurological or psychiatric disease, or were taking medication 
likely to affect the central nervous system. All had normal or corrected-to-normal vision and 
hearing. Other exclusion criteria were sleep disorders, assessed during an in-lab night of sleep 
under polysomnography, body mass index < 18 and > 31 kg/m², smoking, psychoactive drug 
consumption, excessive consumption of caffeine (> 4 cups/day) or alcohol (> 14 units/week), 
diabetes, and shift-work. Participants with clinical levels of depression or anxiety as assessed 
by the Beck Depression Inventory [47] and by the Beck Anxiety Inventory [48], respectively, 
and/or with ongoing pharmacological treatment were excluded. A few participants reached 
mild depression and/or anxiety levels according to Beck scales but this was not considered as 
clinical. Participants with treated (> 6 months) hypertension and hypothyroidism were 
included. All participants showed normal performance on the Mattis Dementia Rating Scale 
[49] [i.e., score > 130/144]. The procedures involving experiments on human subjects were in 
accordance with guidelines on human experimentation and were approved by the local Ethics 
Committee of the Faculty of Medicine (University of Liege). All participants gave their signed 




Neuropsychological examination consisted of a battery of cognitive tasks assessing 
short-term and episodic memory, executive and attentional functions. Original Preclinical 
Alzheimer’s Cognitive Composite 5 (PACC5) score [50,51] was computed as the sum of z-
scores of the following cognitive measures: Free and Total Recall in the Free and Cued 
Selective Reminding Test (FCSRT) [52], Delayed Recall in the Logical Memory Test [53], Total 
score in the Digit Symbol Substitution Test [54], scores in the Verbal Fluency Test for the 
categories of Animals, Fruits and Vegetables (1 min each), and Mini Mental State Examination 
[55]. Here we introduced three changes to the initial PACC5: Mini Mental State Examination 
was replaced by the score from the Mattis Dementia Rating Scale, the Verbal Fluency Test 
score was calculated for the animal category only, and a more recent version of the Digit 
Symbol Substitution Test having a larger range of scores was used [56].  
The episodic memory score was assessed through the Free and Cued Selective 
Reminding Test [52], which, as a list learning test, was proposed by the European Prevention 
of Alzheimer’s Dementia (EPAD) program as a sensitive measure for early cognitive decline 
[57]. The raw score of episodic memory, i.e., the sum of free recall and total recall, was 
converted to z-scores for our analyses. 
Neuropsychological evaluation was performed during 2 sessions taking approximately 
75 min each. As our study was designed for several research objectives, additional 
neuropsychological tasks were included in the assessment, which are not mentioned here.  
Cognitive complaint scores were obtained with the Cognitive Difficulties Scale (CDS; 
[11]). In this questionnaire, participants had to evaluate their cognitive difficulties during the 
last 3 weeks. There were 39 statements (e.g., “I have trouble recalling frequently used phone 
numbers”), where individuals had to indicate their cognitive difficulties on a 5-point Likert 




complaints. This questionnaire was already shown to be a sensitive measure of cognitive 
complaints in studies seeking associations with Aβ burden [58,59]. 
Affective state was based on two questionnaires collected after one of the 
neuropsychological evaluation sessions, the Beck Depression Inventory (BDI) [47], and the 
Beck Anxiety Inventory (BAI) [48]. We computed a composite score for affective state based 
on the average of z-scores of total scores for each questionnaire, and final score was itself 
converted to z-scores. Higher value means worse affective state (i.e., more depression and more 
anxiety). 
Quantitative multi-parametric MRI acquisition was performed on a 3-Tesla MR 
scanner (Siemens MAGNETOM Prisma, Siemens Healthineers, Erlangen, Germany). 
Quantitative maps were obtained by combining images using different parameters sensitive to 
distinct tissue properties. Multi-parameter mapping was based on multi-echo 3D fast low angle 
shot at 1 mm isotropic resolution [60]. This included three datasets with T1, proton density 
(PD), and magnetization transfer (MT)–weighted contrasts imposed by the choice of the flip 
angle (FA = 6° for PD & MT, 21° for T1) and the application of an additional off-resonance 
Gaussian-shaped RF pulse for the MT-weighted acquisition. Fieldmap data for the correction 
of B1 transmit and receiver fields, and B0 inhomogeneity were also acquired. 
Quantitative multi-parametric MRI processing. MRI multi-parameter maps were 
processed with the hMRI toolbox [61] (http://hmri.info) and SPM12 (Welcome Trust Centre 
for Neuroimaging, London, UK) to obtain notably a quantitative MT map as well as segmented 
tissue maps (grey matter, white matter, CSF), using the “unified segmentation” approach. [62]. 
Inter-subject alignment into the standard MNI space was performed with diffeomorphic 





PET acquisition and processing. Aβ PET imaging was performed with radiotracers 
[18F]Flutemetamol for 97 participants and with [18F]Florbetapir for 3 participants on an 
ECAT EXACT HR+ scanner (Siemens, Erlangen, Germany). For all radiotracers, participants 
received a single dose of the respective radio-ligands in an antecubital vein (target dose 185 ± 
10% MBq). Aβ-PET image acquisitions started 85 minutes after injection, and 4 frames of 5 
minutes were obtained. All PET images were reconstructed using filtered back-projection 
algorithm including corrections for measured attenuation  (10 min transmission scan using 
three retractable 68Ge line sources), dead time, random events, and scatter using standard 
software (Siemens ECAT - HR+ V7.1, Siemens/CTI, Knoxville, TN, USA).  
Before proceeding with further PET processing, a PET average image was created using 
all frames. Averaged PET images were first manually reoriented then automatically co-
registered to the structural MT map in subject space. Then, deformation flow-fields derived by 
DARTEL from the MT maps were applied to averaged co-registered PET images [63]. 
Standardized uptake value ratio (SUVR) was calculated using the whole cerebellum as the 
reference region for Aβ-PET [64]. Volumes of interest (VOIs) were determined using the 
masks provided by automated anatomical labelling (AAL) atlas [65]. As Aβ-PET images were 
obtained using 2 radiotracers, their SUVR values were scaled to Centiloid units (CL) for 
common scale [64,66–68]. Finally, we applied two masks for the estimations of Aβ uptake. 
One mask considered global brain Aβ burden and included lateral and medial cortices in 
frontal, parietal, temporal, occipital brain regions, and basal ganglia together with anterior and 
posterior cingulate cortex. Another, more specific mask, considered brain regions which show 
early and rapid Aβ increase in Aβ negative individuals [69], and included posterior cingulate 
cortex (PCC) and precuneus. Given the relatively young age and good health of participants, 




APOE genotyping was performed based on blood sample DNA extraction. Common 
Single Nucleotide Polymorphisms (SNPs) were assessed using Infinium OmniExpress-24 
BeadChip (Illumina, San Diego, CA, USA) based on human genome build hg19 (GRCh37). 
Genotype imputation was performed using the “Sanger Imputation Server” 
(https://imputation.sanger.ac.uk/) by choosing Haplotype Reference Consortium (release 1.1) 
(HRC) [70] as reference panel and the pre-phasing algorithm Eagle2 [71]. APOE ε variants 
were determined by rs7412 and rs429358 SNPs. Participants were classified into ε4 carriers 
(heterozygous and homozygous) and non-carriers, based on their APOE status. 
Statistical analyses. All statistical analyses were performed with SAS 9.4 for Windows 
(SAS Institute, Cary, NC, USA). Generalized linear mixed models (GLMM; PROC 
GLIMMIX) were applied to compute all statistics. Dependent variable distributions were 
estimated using allfitdist function in MATLAB (developed by Mike Sheppard, part of the 
MvCAT package [72]) and set accordingly for each GLMM. Collinearity diagnosis was 
performed on all predictors using Tolerance (TOL) and Variance Inflation Factors (VIF) as 
criteria via PROC REG function on SAS. Degrees of freedom (DF) were estimated using 
Kenward-Roger’s correction. Subject (intercept) effect was included as a random factor. Since 
we computed 5 separate models (prior to the composite model), we defined p-value ≤ 0.01 as 
significant following the Bonferroni correction for multiple comparisons. 
All models included cognitive complaints as the dependent variable, and controlled for 
sex, age, education, and APOE status. GLMM first evaluated the association with cognitive 
performance in two different models, one with PACC5 values, and another with the episodic 
memory score from the PACC5. Then, models sought to evaluate the link between cognitive 
complaints and subclinical affective state. Next GLMMs evaluated the association between 
subjective cognition and AD biomarker (Aβ) in two separate models, one with Aβ burden in 




to early Aβ pathophysiology. A final GLMM sought to evaluate if the significant predictors of 
cognitive complaints that were identified in each previous step (episodic memory, affective 
state, and Aβ) remained significant when assessed simultaneously in one model. Semi-partial 
R2 (Rsp
2) was reported for each significant effect as described previously [73]. 
 
RESULTS 
Descriptive statistics about demographic data, cognitive complaints, affective status, 
cognitive performance, Aβ and APOE status are presented in Table 1. 
 
Links between cognitive complaints and cognitive performance 
We tested whether CDS score was linked to PACC5 and episodic memory measure in 
two separate models. The first GLMM showed no significant association between CDS score 
and PACC5 (Table 2A). The second model revealed a significant negative association between 
CDS score and episodic memory measure, indicating that a higher level of cognitive complaints 
is linked to worse performance on the FCSRT task, as well as an uncorrected positive 
association between education and CDS in the second model, such that higher education may 
be associated with higher cognitive concerns (Table 2B; Figure 1A and 1D). Sex, age and 
APOE allele (i.e., ε4 carriers vs. non-carriers) were not associated with cognitive complaints 
in either models. 
 
Association between level of cognitive complaints and affective state 
GLMM showed that the level of cognitive complaints was positively associated with 




(Table 3; Figure 1B). In contrast, sex, age, education and APOE genotype were not associated 
with cognitive complaints. 
 
Relationship between level of cognitive complaints and Aβ burden 
Then, we tested whether CDS score was associated to global Aβ burden (i.e., using a 
brain mask covering the entire brain, except the cerebellum) and to early amyloid 
pathophysiology regions (i.e., posterior cingulate cortex and precuneus, see [69]). The first 
GLMM yielded a positive association between CDS score and global Aβ accumulation (Table 
4A; Figure 1C), but at uncorrected p value level only. In contrast, the second GLMM did not 
show any significant association between CDS score and Aβ over early AD pathophysiology 
regions (Table 4B). Again, sex, age, education and APOE genotype were not associated with 
cognitive complaints. 
 
Simultaneous associations between level of cognitive complaints and episodic memory, 
affective state, and Aβ burden 
In our final step, we considered jointly the single parameters significantly related to 
CDS score at uncorrected (or corrected in case of FCSRT score) p values in the previous 
models. This final GLMM revealed that episodic memory performance, affective state, and 
global Aβ remained associated at similar significance level with subjective cognitive score 
(Table 5; Figure 1). Moreover, education was significantly positively linked to CDS, 
indicating that higher education may be associated with higher cognitive concerns (Table 5; 







SCD is a recent concept that might represent a preclinical stage within AD 
pathophysiology indicative of an increased risk for developing AD [7]. Its links with various 
cognitive or physiological aspects have been assessed multiple times already, but the 
simultaneous association with several behavioral and brain aspects remains scarce, especially 
in individuals not seeking for clinical help. The main objective of this study was therefore to 
assess how subjective feeling of one’s own cognitive abilities is related to objective cognitive 
outcomes known as early markers of AD (global cognitive outcome using PACC5 measure, 
and verbal episodic memory performance for a list learning task), concomitant subclinical 
affective state, and in-vivo Aβ PET global brain uptake (taken as a continuous value) in 
cognitively normal and amyloid-β negative late middle-aged individuals, controlling for sex, 
age, education and APOE status.  
To evaluate cognitive complaints we used the Cognitive Difficulties Scale [11], which 
meets current consensus as the optimal method to assess one’s perception of cognitive status 
[6,58,59]. Our analyses revealed that a higher level of cognitive complaints was related to a 
worse score on the episodic memory task, but not to PACC5 outcome. We further report that 
cognitive complaints may also be linked to worse subjective affective state, while they were 
also potentially associated with a higher Aβ brain accumulation when considered over the 
entire brain, but not when focusing only on the brain regions considered to be first affected by 
Aβ accumulation over the course of AD pathophysiology. Since these correlates of cognitive 
complaints remained similarly associated with CDS when included together in a single 
statistical model, we further suggest that episodic memory, together with a potential 
contribution of affective state and whole-brain Aβ burden, explain at least partially distinct 




It is important to note that the definition of SCD posits that cognitive complaints are 
not necessarily limited to the memory domain, but may also include other cognitive domains 
[5,74]. Previous cross-sectional studies have also reported that, while remaining clinically 
normal, a higher SCD level is related to lower performance on global cognition [8,9,75,76], 
and more specific cognitive functions, including verbal episodic memory and executive 
functions [10]. Our results show that, in late midlife, cognitive complaints in cognitively 
normal individuals are associated with episodic memory functioning, but not with a global 
measure of cognition known to be sensitive to the earliest AD-related cognitive changes. We 
may therefore extend previous findings by showing that if cognitive complaints do not reach a 
status leading to help seeking, which would allow formal clinical SCD diagnosis, we presume 
that episodic memory performance may be the main indicator one uses to judge his/her 
cognitive status.  
This link must have underlying neural correlates, including changes in brain structural 
and functional integrity. Atrophy in the regions of medial temporal lobe (MTL) is often viewed 
as the primary target to account for alterations in episodic memory. For example, Perrotin and 
colleagues have reported that higher level of self-reported cognitive difficulties among seniors 
was associated with hippocampal atrophy, at least in a group seeking medical help [58]. The 
decline in verbal episodic memory, measured using the same FCSRT task as in our study, was 
also related to MTL atrophy in healthy seniors (mean age 72.7 years) in a longitudinal study 
[77]. Episodic memory functioning is not only limited to MTL integrity, but also includes 
medial and lateral prefrontal cortex, precuneus, posterior cingulate cortex [78], regions which 
were included in our global brain Aβ PET estimation.  
Our analyses revealed that cognitive complaints are weakly related to a higher global 
Aβ burden (at uncorrected significance level), but not in the specific mask related to early Aβ 




previous studies reported that a higher level of SCD is related to a higher Aβ PET accumulation 
[32–34,37,58,59,80–83]. Most of previous studies have included, however, older participants 
(around 70 years) from both the general community and memory clinic, thus concentrating on 
SCD individuals with increased risk for AD [17]. Here, we add therefore that cognitive 
complaints in healthy midlife (mean age 59 years) community-based individuals, not seeking 
for medical help, could also correspond to a higher global Aβ concentration, even when the 
values of the latter biomarker remain in sub-threshold level for amyloid positivity. Our attempt 
to investigate the regional specificity of the association lead to a negative result when including 
the brain regions first affected by Aβ plaque progression. It seems therefore that cognitive 
complaints may reflect somehow the diffused global low level of Aβ rather the initial step of 
Aβ brain pathology. Furthermore, our results related to Aβ may be also affected by PET 
processing method. We used two radiotracers to estimate Aβ burden in global and specific 
brain masks. In order to standardize uptake values of two different radiotracers, we have 
validated standardized Centiloid pipeline according to our particular data [64,66,67] and 
computed scaling equations allowing to convert SUVR of two radiotracers into common 
Centiloid units (CL). However, this standardized pipeline has one possible limitation, as it does 
not include partial volume correction (PVC) as a PET pre-processing step, which is often used 
to correct for spill-in effects from adjacent tissue classes [84]. Therefore, in Supplementary 
Material, we have repeated our statistical analyses with Aβ data using PVC, but only with one 
radiotracer (Flutemetamol), as inclusion of this pre-processing step does not allow to apply 
Centiloid scaling equations to convert the SUVR values of two radiotracers into CL. Our 
statistical models in Supplementary Material showed that Aβ was no longer a significant 
predictor of cognitive complaints. These results may be explained by a smaller sample size 
than the main sample, or by the fact that PVC can sometimes increase sensitivity to inaccuracy 




firm conclusions about the exact role of Aβ burden in the context of cognitive complaints. Yet, 
further investigations are needed to confirm our relatively weak association and establish 
whether the regional distribution of Aβ matters in its association with cognitive complaints 
using voxel-based analyses. 
Surprisingly and contrary to our hypothesis, we found no associations between PACC5 
score and cognitive complaints. It might be that PACC5, while considered as a sensitive 
measure, is limited by one of its components, the Mini Mental State Examination (MMSE) 
score, which in our study was replaced by the Mattis Dementia Rating Scale. Both scores are 
designed as short dementia screening tests, but display a ceiling effect in cognitively healthy 
individuals [86], and it was even suggested that PACC score should be computed without such 
a measure [87]. In addition, our study did not assess the associations of cognitive complaints 
with other specific cognitive domains (e.g., processing speed, attention, executive functions, 
language, visuospatial abilities), thus, we cannot dismiss the possibility of other cognitive 
correlates of cognitive complaints. 
On top of the link between memory performance and Aβ burden, and not surprisingly, 
we found that cognitive complaints may be linked (at relatively low but still uncorrected p 
value level) to worse affective state in a healthy study sample that do not meet criteria for a 
clinical affective condition. Previous studies have also reported that SCD individuals show 
higher levels of depressive symptoms [8,33,40,42] and anxiety [43,58,88] than healthy 
controls. According to current views, worse affective state may reflect reaction to cognitive 
complaints [42], or may have a common or a separate underlying cause [17], such as 
hypothalamic-pituitary-adrenal axis hyperactivity [89]. 
While it was not our main goal, we found that higher education is potentially related to 




education is linked to SCD [8,90,91]. Interestingly, it was also shown that when better educated 
individuals reached objective cognitive decline, they reported more self-perceived difficulties, 
whereas lower educated seniors did not show concomitant cognitive complaints when reaching 
objective cognitive decline [92]. It may be that individuals with a higher educational status 
have also a better self-perception of their cognitive status. Alternatively, it may also be that 
high cognitive efficiency in better educated individuals is more important to them due to 
professional or more personal reasons. The concept of cognitive reserve also suggests that in 
the presence of brain pathology, persons with lower education would reach clinically 
significant cognitive impairment faster than individuals with better education, who may be able 
to compensate for longer time but can sometimes express higher level of cognitive complaints 
[93]. For example, one study demonstrated that the link between SCD and amyloid level 
becomes stronger with greater educational attainment [94]. 
We neither observed an effect of APOE ε4 status for the level of cognitive complaints.  
A systematic review [95] reported APOE ε4 allele frequency is comparable between SCD 
individuals and healthy controls (see however [96]). Nonetheless,  it seems that APOE ε4 
carrier status in SCD individuals increases the probability for clinical progression to MCI [97]. 
These results come from studies which mostly studied clinically defined SCD individuals, and 
not cognitive complaint in a healthy population, as it was in our case.  
While previous data indicate that age is associated to the level of memory complaints 
[33], and that the age for onset of SCD [17] can even be more predictive of dementia risk 
[34,98], we did not observe an association between age and level of cognitive complaints. 
However, the age range was between 50 and 69 years in our study, thus limiting the possible 
age effect for cognitive complaints.. 
From a more clinical viewpoint, it seems important to emphasize that the symptom of  




associated to other minimally invasive biomarkers to identify high-risk individuals in primary 
care setting. For example, MRI-based lower hippocampal volume was related to poorer 
memory performance in a group of elderly individuals with subjective memory complaints 
[99]. Blood-based biomarkers are also gaining attention, as it was reported that high folate and 
low bilirubin levels in SCD individuals were related to cognitive decline at 3-year follow-up 
[100], while decreased total antioxidant and increased serum homocysteine levels were related 
to more subjective memory complaints [101]. Moreover, tau protein burden is also a main AD-
related biomarkers [4]. Interestingly, blood-based tau biomarker (plasma tau phosphorylated at 
threonine 181; P-tau 181) was recently suggested as an early AD biomarker, even preceding 
PET-tau [102]. Furthermore, the presence of cardiovascular disease and depressive symptoms 
history may also indicate about possible progression or reverting in cognitive decline [103]. 
We stress that our study bears some limitations, the first one being its cross-sectional 
nature which controls less efficiently for different environmental effects or life experiences, 
and, therefore, does not allow to approach causal interpretation as longitudinal approaches 
would do. For instance, the increase in Aβ over time may be more important for cognitive 
decline than baseline amyloid level [104]. Another possible limitation in our study is selection 
bias due to the requirements of the larger project in which our volunteers were enrolled. Our 
participants underwent quite extensive screening for health and affective status, consumption 
of psychoactive substances (e.g., alcohol, drugs, caffeine), and their educational level was high. 
This type of selection bias is however also present in SCD studies, sometimes including highly 
educated volunteers from academic memory clinic or community [33,80]. In addition, we did 
find a weak behavioral and Aβ correlates of cognitive complaints despite this rather excellent 
health status, preventing any bias from potential comorbidities or unspecific heath conditions. 
Finally, our study did not include the evaluation of worry associated with subjective cognitive 




therefore included in SCD plus category [7,17]. As we evaluated healthy volunteers from 
general population and many of them had quite low level of cognitive complaints (see Table 
1), we did not ask a question about possible worry over their cognitive status. Future studies 
assessing similar population may particularly consider inclusion of the question about worry, 
as it might better characterize cognitive complaints. 
To sum up, our results provides new insights about the associations between cognitive 
complaints, objective cognition and AD biomarker status. We demonstrate that as early as in 
late midlife, cognitive complaints may be considered as an important marker for higher sub-
threshold amyloid accumulation. Moreover, we show that, beyond brain integrity, perception 
of cognitive status has some actual ground which relies mostly on the episodic memory and 
affective domains. Future studies are needed to untangle how cognitive complaints in 
community-based late middle-aged population is related to longitudinal changes in objective 
cognition and AD biomarker correlates.  
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 Mean SD Min Max 
Demographical data     
Age, years 59.16 5.22 50.00 69.00 
Sex, female, n (%) 60 (69%) 
Ethnic status, Caucasian, n (%) 87 (100%) 
Education, years 15.10 3.07 9.00 25.00 
Educational level:  
Primary School, n (%) .0 (0%) 
Secondary School, n (%) 23 (26.4%) 
Bachelor degree, n (%) 33 (37.9%) 
Master degree, n (%) 25 (28.7%) 
PhD or higher, n (%) 6 (6.9%) 
Subjective factors      
Subjective cognitive complaints (CDS) 28.77 19.42 .0 95.00 
Depression (BDI) 5.21 4.53 .0 17.00 
Anxiety (BAI) 2.98 3.34 .0 17.00 
Objective cognition      
PACC5 score .0 2.93 -7.92 8.21 
FCSRT, Free and Total recall 81.09 6.63 66.00 92.00 
Logical Memory Task, delayed recall 12.26 3.79 3.00 22.00 
DSST, total 2 min score 73.10 12.66 39.00 99.00 
Semantic Fluency Test, 1 min score 20.41 4.21 13.00 37.00 
Mattis Dementia Rating Scale 142.48 1.92 134.00 144.00 
Aβ accumulation     
Global Mask, CL -5.15 5.65 -15.85 7.36 
PCC and Precuneus Mask, CL -.10 7.89 -23.93 20.72 
APOE  
APOE ε4 carriers, n (%) 16 (18.4%) 
APOE ε4 non-carriers, n (%) 71 (81.6%) 
 
Table 1. Descriptive statistics of demographical data, subjective factors, objective cognition, 
Aβ and APOE (N = 87).  
SD, Standard Deviation; CDS, Cognitive Difficulties Scale; BDI, Beck Depression Inventory; 
BAI, Beck Anxiety Inventory; FCSRT, Free and Cued Selective Reminding Test; DSST, Digit 
Symbol Substitution Test; Aβ, amyloid-β; CL, Centiloid units; PCC, posterior cingulate cortex; 






Model A Estimate ± SE F value (df) P CI 
Sex*  -.13 ± .21 .38 (1,81) .542 [-.54  .29] 
Age -.03 ± .09 .13 (1,81) .720 [-.21  .15] 
Education  .18 ± .10 3.34 (1,81) .071 [-.02  .37] 
APOE -.06 ± .23 .06 (1,81) .801 [-.52  .40] 
PACC5 -.15 ± .10 2.42 (1,81) .124 [-.35  .04] 
  
Model B Estimate ± SE F value (df) P CI 
Sex*  -.18 ± .20 .80 (1,81) .373 [-.56  .21] 
Age -.02 ± .09 .04 (1,81) .851 [-.19  .16] 
Education  .18 ± .09 4.11 (1,81) .046 (Rsp
2=.05) [.003  .36] 




-.28 ± .09 9.67 (1,81) .003 (Rsp2=.11) [-.46  -.10] 
  
 
Table 2. Statistical outcome of the GLMM seeking for associations between cognitive 
complaint level (dependent variable), and: A: PACC5; B: episodic memory measure.  
SE, Standard Error; df, degrees of freedom; CI, confidence interval of 95%; APOE, 
Apolipoprotein E; FCSRT, Free and Cued Selective Reminding Test. Grey background 
represents control variables included in all GLMM. Significant associations at uncorrected 
level are in italic, while those meeting criteria of correction for multiple tests are in bold.  












 Estimate ± SE F value (df) P CI 
Sex*  .04 ± .19 .05 (1,81) .825 [-.34  .43] 
Age -.01 ± .09 .02 (1,81) .876 [-.19  .16] 
Education  .14 ± .09 2.54 (1,81) .115 [-.04  .32] 
APOE -.04 ± .23 .04 (1,81) .844 [-.50  .41] 
Affective state1 .22 ± .09 6.26 (1,81) .014 (Rsp
2=.07) [.05  .40] 
  
 
Table 3. Statistical outcome of the GLMM seeking for associations between cognitive 
complaint level (dependent variable) and affective state.  
SE, Standard Error; df, degrees of freedom; CI, confidence interval of 95%; Rsp2, Semi-partial 
R2; APOE, Apolipoprotein E. Grey background represents control variables included in all 
GLMM. Significant associations at uncorrected level are in italic, while those meeting criteria 
of correction for multiple tests are in bold.  
*Sex: 1 = male; 2 = female.  















Model A Estimate ± SE F value (df) P CI 
Sex*  .04 ± .20 .03 (1,81) .853 [-.36  .43] 
Age -.04 ± .09 .19 (1,81) .665 [-.22  .14] 
Education .16 ± .09 3.07 (1,81) .083 [-.02  .34] 
APOE .04 ± .24 .04 (1,81) .849 [-.42  .51] 
Aβ (global) .19 ± .09 4.02 (1,81) .048 (Rsp
2=.05) [.001  .38] 
  
Model B Estimate ± SE F value (df) P CI 
Sex*  -.01 ± .20 .0 (1,81) .977 [-.41  .40] 
Age -.03 ± .09 .14 (1,81) .708 [-.22  .15] 
Education .14 ± .10 2.10 (1,81) .152 [-.05  .33] 
APOE -.04 ± .24 .03 (1,81) .859 [-.52  .43] 
Aβ (specific) .03 ± .10 .11 (1,81) .737 [-.16  .23] 
  
 
Table 4. Statistical outcome of the GLMM seeking for associations between cognitive 
complaint level (dependent variable) and: A: Aβ global mask; B: Aβ specific mask.  
SE, Standard Error; df, degrees of freedom; CI, confidence interval of 95%; Rsp2, Semi-partial 
R2; APOE, Apolipoprotein E; Aβ, amyloid-β. Grey background represents control variables 
included in all GLMM. Significant associations at uncorrected level are in italic, while those 
meeting criteria of correction for multiple tests are in bold.  













 Estimate ± SE F value (df) P CI 
Sex*  -.05 ± .19 .06 (1,79) .812 [-.43  .34] 
Age -.003 ± .08 .0 (1,79) .971 [-.17  .16] 
Education .21 ± .09 6.07 (1,79) .016 (Rsp2=.07) [.04  .39] 




-.24 ± .09 7.59 (1,79) .007 (Rsp2=.09) [-.42  -.07] 
Affective state1 .20 ± .08 5.50 (1,79) .022 (Rsp2=.06) [.03  .37] 
Aβ (global) .18 ± .09 4.10 (1,79) .046 (Rsp2=.05) [.003  .35] 
  
 
Table 5. Statistical outcome of the GLMM seeking for associations between cognitive 
complaint level (dependent variable), episodic memory, affective state, and Aβ global mask. 
SE, Standard Error; df, degrees of freedom; CI, confidence interval of 95%; Rsp2, Semi-partial 
R2; APOE, Apolipoprotein E; FCSRT, Free and Cued Selective Reminding Test; Aβ, amyloid-
β. Grey background represents control variables included in all GLMM.  
*Sex: 1 = male; 2 = female.  


















Figure 1. Scatter plots visualizing the associations between cognitive complaints (higher score 
refers to worse cognitive difficulties) and A: Memory performance (higher is better); B: 
Affective state (higher is worse); C: Aβ accumulation in global brain mask (higher means 
worse); D: Education (higher is better). Simple regressions were used for visual display only, 












Statistical models having Aβ burden estimation with PET PVC and the gray matter of the 
cerebellum as the reference region (N = 84) 
 
Model A Estimate ± SE F value (df) P CI 
Sex*  .07 ± .20 .12 (1,78) .732 [-.33  .46] 
Age -.04 ± .09 .22 (1,78) .639 [-.23  .14] 
Education .14 ± .09 2.28 (1,78) .135 [-.04  .32] 




.08 ± .09 .67 (1,78) .416 [-.11  .26] 
  
Model B Estimate ± SE F value (df) P CI 
Sex*  .06 ± .20 .09 (1,78) .768 [-.34  .45] 
Age -.03 ± .09 .14 (1,78) .708 [-.22  .15] 
Education .12 ± .09 1.74 (1,78) .192 [-.06  .31] 




-.07 ± .09 .51 (1,78) .479 [-.26  .12] 
  
 
Supplementary Table 1. Statistical outcome of the GLMM seeking for associations between 
cognitive complaint level (dependent variable) and: A: Aβ global mask; B: Aβ specific mask.  
SE, Standard Error; df, degrees of freedom; CI, confidence interval of 95%; Rsp2, Semi-partial 
R2; APOE, Apolipoprotein E; Aβ, amyloid-β; PVE, partial volume effect. Grey background 
represents control variables included in all GLMM. For PET PVC, we have used Müller-
Gärtner method on PETPVE12 toolbox [84] running in SPM12 environment. 






Statistical models having Aβ burden estimation without PET PVC but with the gray matter 
of the cerebellum as the reference region (N = 84) 
 
Model A Estimate ± SE F value (df) P CI 
Sex*  .10 ± .20 .25 (1,78) .620 [-.29  .49] 
Age -.05 ± .09 .26 (1,78) .613 [-.23  .13] 
Education .15 ± .09 2.64 (1,78) .108 [-.03  .33] 




.12 ± .09 1.81 (1,78) .182 [-.06  .31] 
  
Model B Estimate ± SE F value (df) P CI 
Sex*  .07 ± .20 .13 (1,78) .715 [-.33  .48] 
Age -.04 ± .09 .17 (1,78) .683 [-.22  .14] 
Education .14 ± .09 2.21 (1,78) .141 [-.05  .32] 




.01 ± .10 .01 (1,78) .907 [-.18  .20] 
  
 
Supplementary Table 2. Statistical outcome of the GLMM seeking for associations between 
cognitive complaint level (dependent variable) and: A: Aβ global mask; B: Aβ specific mask.  
SE, Standard Error; df, degrees of freedom; CI, confidence interval of 95%; Rsp2, Semi-partial 
R2; APOE, Apolipoprotein E; Aβ, amyloid-β; PVE, partial volume effect. Grey background 
represents control variables included in all GLMM.  
*Sex: 1 = male; 2 = female. 
 
 
 
